Comparative Pharmacology
Head-to-head clinical analysis: COLESTID versus QUESTRAN LIGHT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLESTID versus QUESTRAN LIGHT.
COLESTID vs QUESTRAN LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver.
5-10 g orally once or twice daily, maximum 30 g/day.
4 grams (one packet or one level scoop) orally once or twice daily, with a maximum of 24 grams per day. Dose may be increased by 4 grams daily at weekly intervals as needed.
None Documented
None Documented
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable; cholesteryamine resin is not absorbed systemically; half-life refers to GI transit time (~2-4 hours).
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily fecal (as resin-bound bile acids); less than 0.05% renally excreted unchanged.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant